DataSet Record GDS5267: Expression Profiles Data Analysis Tools Sample Subsets
Title: Cyclin-dependent kinase inhibitor R547 effect on prostate cancer cell line: dose response and time course
Cluster AnalysisGDS5267 Cluster Image
Summary: Analysis of DU145 prostate cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.
Organism: Homo sapiens
Platform: GPL570: [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
  • Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther 2009 Sep;8(9):2517-25. PMID: 19755512
Reference Series: GSE15392 Sample count: 45
Value type: count Series published: 2009/03/26